What is Disc Medicine's R&D?

Disc Medicine (IRON) reported R&D of $45.9M in Q1 2026.

How has Disc Medicine's R&D changed year-over-year?

Disc Medicine's R&D increased by 65.3% year-over-year, from $27.76M to $45.9M.

What is the long-term trend for Disc Medicine's R&D?

Over 3 years (2022 to 2025), Disc Medicine's R&D has grown at a 72.2% compound annual growth rate (CAGR), from $33.44M to $170.64M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Disc Medicine (IRON) R&D — Quarterly & Annual

Screener

R&D at other companies

Bristol-Myers SquibbBMY

$2.96B+14.7%

Protagonist TherapeuticsPTGX

$42.06M+13.6%

Agios PharmaceuticalsAGIO

$100.75M+9.6%

Beam TherapeuticsBEAM

$104.52M+5.8%

BridgeBio PharmaBBIO

$149.45M+34.4%

PTC TherapeuticsPTCT

$100.87M-7.4%

Segments

By product

See full

Internal Research And Development$11.31M+67.6%

Bitopertin$9.34M+10.7%

DISC Three Four Zero Five$9.19M+451%

DISC Zero Nine Seven Four$8.11M+32.5%

Other Research$2.17M+18.2%

Other financials

Income statement

See full

Operating income-$69.5M-74.0%

Net income-$63.5M-86.3%

EPS (diluted)-$1.65-61.8%

Balance sheet

See full

Cash & equivalents$88.9M-27.5%

Total debt$31.1M+1.4%

Total equity$688.4M+4.3%

Total assets$750.2M+5.8%

Cash flow

See full

Operating cash flow-$62.2M-50.4%

CapEx--100%

Free cash flow-$62.2M-47.4%

Valuation

See full

Market cap$2.97B+46.0%

Enterprise value$2.92B+50.2%

Returns & leverage

See full

Return on equity-35.8%+41.3pp

Debt / equity0×0.0×

Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Disc Medicine’s 10-Q, filed May 5, 2026.

Filed: May 5, 2026, 8:33 AM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001193125-26-205192

Line item	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Operating expenses:
Research and development	$45,904	$27,763
Selling, general and administrative	23,620	12,183
Total operating expenses	69,524	39,946
Loss from operations	(69,524)	(39,946)
Other income (expense), net:
Interest income	6,893	6,880
Interest expense	(844)	(897)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Disc Medicine's R&D?: Disc Medicine (IRON) reported R&D of $45.9M in Q1 2026.
How has Disc Medicine's R&D changed year-over-year?: Disc Medicine's R&D increased by 65.3% year-over-year, from $27.76M to $45.9M.
What is the long-term trend for Disc Medicine's R&D?: Over 3 years (2022 to 2025), Disc Medicine's R&D has grown at a 72.2% compound annual growth rate (CAGR), from $33.44M to $170.64M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.